Formulation
US8466139B2 · kind B2 · utility
15Cited by
16References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 4, 2012 |
| Grant date | Jun 18, 2013 |
| Priority date | — |
| Expiry date | Sep 4, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/44
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol, more particularly to a formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.